ignals from lymphocytes in colon cancer
The area of tumour immunology is often characterised as one of sustained optimism, yet although this field has enriched our knowledge of basic immunology, little has emerged to benefit the cancer patient. This may now The immunohistochemical study by Mulder et al elegantly confirms and extends several of the features of earlier work in this field, which has mainly been based on flow cytometric and biochemical analysis. Relative to normal mucosa, Mulder et al find that the numbers ofTCR 4 expressing lymphocytes in tumours were decreased in Dukes's A and D colorectal carcinomas, being lowest in Dukes's D tumours. This adds to previous findings that the intensity of TCR 4 expression in peripheral blood lymphocytes of patients with colorectal carcinoma is decreased with more advanced tumour stages, as measured with flow cytometry and biochemical methods. 5 6 As Mulder et al find that the number of TCR + lymphocytes decreased in Dukes's A carcinomas, their results suggest that TCR t downregulation in TIL is a relatively early event in the interaction between a tumour and the immune system. In contrast, they describe an increase in the numbers of GrB expressing lymphocytes in the early stage of colorectal tumours, similar to earlier observations by Nakanishi et al. 9 The authors infer that as the expression of this molecule involved in the cytolysis of tumour cells requires both TCR triggering and signalling via a costimulatory receptor some immune stimulation still takes place in Dukes's A carcinoma. In Dukes's D carcinomas, however, GrB expressing cells had disappeared from the tumour tissue, which can explain the lack of cytotoxic activity of TIL cells.
The number of TCR t expressing lymphocytes in tumours was decreased in the tumour relative to normal mucosa, similar to the 'gradient' of t expression that was previously described moving from the TIL to the normal mucosa and peripheral blood in patients with colorectal carcinomas. 5 The authors speculate that this may point at the involvement of tumour derived factors as the responsible mechanism, and give some evidence in support of this showing that both TCR 4 and GrB were rapidly restored during in vitro culture. These tumour derived factors may be secreted by the tumour cells or by tumour infiltrating mononuclear cells, the latter alternative being supported by recent observations that tumour associated macrophages as a result of coincubation with autologous T cells from cancer patients can induce decreased expression of TCR t.°R egardless of the underlying mechanism, measuring TCR t expression might provide vital information that can be used to follow up and optimise immunotherapy of cancer patients. Immunohistochemical analysis, for example, of biopsy specimens taken from the site of antitumour vaccination, or flow cytometric assays of T lymphocytes from peripheral blood might provide a particularly convenient way of doing this on a routine basis.
The possibility that measuring expression of TCR t will be of prognostic value should be explored in patients with colorectal carcinoma and other types of human tumours. Research aimed at developing drugs that can counteract suppression of anti-tumour activity, normalising the expression of TCR t and GrB molecules in cancer patients, and which should be given in combination with active or adoptive immunotherapy, should provide new and promising avenues for the treatment of cancer ROLF KIESSLING Professor ofExperimental Oncology, Department ofMicrobiology and Tumorbiology, Karolinska institute, Stockholm, Sweden
